7MM hidradenitis suppurativa market to quadruple by 2034

Thanks to the approval and uptake of next-generation biologics.

The hidradenitis suppurativa (HS) market across the seven major pharmaceutical markets (7MM), valued $1.84b in 2024, is expected to reach $7.83b in 2034, at a compound annual growth rate of 15.6%, said GlobalData.

The sector’s expansion is attributed to the approval and uptake of next-generation biologics and small molecules with novel mechanisms of action.

The US will lead market growth, accounting for over 70% of sales in 2024, due to a larger diagnosed population, wider biologic access, and premium pricing.

However, HS care is hindered by diagnostic delays averaging up to 10 years, leading to irreversible tissue damage, according to Asiyah Nawab, Healthcare Analyst at GlobalData.

“Furthermore, most biologic treatments are indicated for moderate-to-severe disease, leaving early-stage (Hurley Stage I) patients without effective interventions,” Nawab added.

7MM = US, France, Germany, Italy, Spain, UK, and Japan